Literature DB >> 21951551

Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases.

Z A Qureshi1, D L Paterson, A Y Peleg, J M Adams-Haduch, K A Shutt, D L Pakstis, E Sordillo, B Polsky, G Sandkovsky, M K Bhussar, Y Doi.   

Abstract

Clin Microbiol Infect 2012; 18: 887-893 ABSTRACT: A multicentre, case-control study was conducted to assess risk factors and patient outcomes of bacteraemia caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) and Klebsiella pneumoniae carbapenemases (KPCs). One hundred and five and 20 patients with bacteraemia caused by ESBL-producing and KPC-producing organisms were matched to controls who had bacteraemia caused by non-ESBL/KPC-producing organisms, respectively. Independent risk factors for ESBL production included admission from a nursing home (OR 4.64; 95% CI 2.64-8.16), chronic renal failure (OR 2.09; 95% CI 1.11-3.92), the presence of a gastrostomy tube (OR 3.36; 95% CI 1.38-8.18), length of hospital stay before infection (OR 1.02; 95% CI 1.01-1.03), transplant receipt (OR 2.48; 95% CI 1.24-4.95), and receipt of antibiotics with Gram-negative activity in the preceding 30 days (OR 1.76; 95% CI 1.00-3.08). Twenty-eight-day crude mortality rates for patients infected with ESBL-producing or KPC-producing organisms and controls were 29.1% (34/117) and 19.5% (53/272), respectively (OR 1.70; 95% CI 1.04-2.80). On multivariate analysis, inadequate empirical therapy (OR 2.26; 95% CI 1.18-4.34), onset of bacteraemia while in the intensive-care unit (OR 2.74; 95% CI 1.47-5.11), Apache II score (OR 1.17; 95% CI 1.12-1.23) and malignancy (OR 2.66; 95% CI 1.31-5.41) were independent risk factors for mortality. CTX-M was the most common ESBL type in Escherichia coli, whereas SHV predominated in Klebsiella spp. and Enterobacter spp.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21951551      PMCID: PMC3252485          DOI: 10.1111/j.1469-0691.2011.03658.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  25 in total

1.  Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.

Authors:  Zubair A Qureshi; David L Paterson; Diana L Pakstis; Jennifer M Adams-Haduch; Gabriel Sandkovsky; Emilia Sordillo; Bruce Polsky; Anton Y Peleg; Manveen K Bhussar; Yohei Doi
Journal:  Int J Antimicrob Agents       Date:  2010-11-13       Impact factor: 5.283

2.  Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation.

Authors:  D A Schiappa; M K Hayden; M G Matushek; F N Hashemi; J Sullivan; K Y Smith; D Miyashiro; J P Quinn; R A Weinstein; G M Trenholme
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

3.  Prevalence and risk factors of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility.

Authors:  G Mendelson; V Hait; J Ben-Israel; D Gronich; E Granot; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

4.  Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.

Authors:  Theoklis E Zaoutis; Monika Goyal; Jaclyn H Chu; Susan E Coffin; Louis M Bell; Irving Nachamkin; Karin L McGowan; Warren B Bilker; Ebbing Lautenbach
Journal:  Pediatrics       Date:  2005-04       Impact factor: 7.124

5.  Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.

Authors:  Andrea Endimiani; Francesco Luzzaro; Gioconda Brigante; Mariagrazia Perilli; Gianluigi Lombardi; Gianfranco Amicosante; Gian Maria Rossolini; Antonio Toniolo
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

Authors:  Simona Bratu; David Landman; Robin Haag; Rose Recco; Antonella Eramo; Maqsood Alam; John Quale
Journal:  Arch Intern Med       Date:  2005-06-27

7.  Increased mortality associated with a clonal outbreak of ceftazidime-resistant Klebsiella pneumoniae: a case-control study.

Authors:  Abdul Qavi; Sorana Segal-Maurer; Noriel Mariano; Carl Urban; Carl Rosenberg; Janice Burns; Tom Chiang; James Maurer; James J Rahal
Journal:  Infect Control Hosp Epidemiol       Date:  2005-01       Impact factor: 3.254

8.  Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.

Authors:  J Wiener; J P Quinn; P A Bradford; R V Goering; C Nathan; K Bush; R A Weinstein
Journal:  JAMA       Date:  1999-02-10       Impact factor: 56.272

9.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.

Authors:  Bin Du; Yun Long; Hongzhong Liu; Dechang Chen; Dawei Liu; Yingchun Xu; Xiuli Xie
Journal:  Intensive Care Med       Date:  2002-10-17       Impact factor: 17.440

10.  International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

View more
  17 in total

1.  The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.

Authors:  Meredith G Jernigan; Ellen G Press; M Hong Nguyen; Cornelius J Clancy; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).

Authors:  Mariana Castanheira; Sarah E Farrell; Lalitagauri M Deshpande; Rodrigo E Mendes; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

3.  Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.

Authors:  J-H Ko; N R Lee; E-J Joo; S-Y Moon; J-K Choi; D A Park; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-25       Impact factor: 3.267

4.  Faropenem disks for screening of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae.

Authors:  Fupin Hu; Chulsoo Ahn; Jessica A O'Hara; Yohei Doi
Journal:  J Clin Microbiol       Date:  2014-09       Impact factor: 5.948

5.  Characterization of a Novel IncHI2 Plasmid Carrying Tandem Copies of blaCTX-M-2 in a fosA6-Harboring Escherichia coli Sequence Type 410 Strain.

Authors:  Qinglan Guo; Baixing Ding; Thomas Jové; Nicole Stoesser; Vaughn S Cooper; Minggui Wang; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

6.  Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.

Authors:  Zubair A Qureshi; David L Paterson; Brian A Potoski; Mary C Kilayko; Gabriel Sandovsky; Emilia Sordillo; Bruce Polsky; Jennifer M Adams-Haduch; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

7.  Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae: a retrospective cohort study.

Authors:  Min Jae Kim; Kyoung-Ho Song; Nak-Hyun Kim; Pyoeng Gyun Choe; Wan Beom Park; Ji Hwan Bang; Eu Suk Kim; Sang Won Park; Hong Bin Kim; Hyo-Suk Lee; Myoung-Don Oh; Nam Joong Kim
Journal:  Hepatol Int       Date:  2014-06-08       Impact factor: 6.047

8.  Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae.

Authors:  Yun Liao; Guang-Hui Hu; Yun-Fei Xu; Jian-Ping Che; Ming Luo; Hai-Min Zhang; Bo Peng; Xu-Dong Yao; Jun-Hua Zheng; Min Liu
Journal:  Exp Ther Med       Date:  2017-01-16       Impact factor: 2.447

9.  Molecular and epidemiological characterization of IMP-type metallo-β-lactamase-producing Enterobacter cloacae in a Large tertiary care hospital in Japan.

Authors:  Kayoko Hayakawa; Tohru Miyoshi-Akiyama; Teruo Kirikae; Maki Nagamatsu; Kayo Shimada; Kazuhisa Mezaki; Yuko Sugiki; Emi Kuroda; Shiho Kubota; Nozomi Takeshita; Satoshi Kutsuna; Masayoshi Tojo; Norio Ohmagari
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

10.  Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.

Authors:  J A Sutcliffe; W O'Brien; C Fyfe; T H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.